SELECTION OF OVARIAN STIMULATION PROTOCOL IS RELATED TO IVF TREATMENT OUTCOME IN WOMEN 35 YEARS OF AGE AND OLDER

被引：13

作者：

CSEMICZKY, G ^{[1
]}

HAGENFELDT, K ^{[1
]}

WRAMSBY, H ^{[1
]}

机构：

[1] KAROLINSKA HOSP,DEPT WOMAN & CHILD HLTH,DIV OBSTET & GYNECOL,S-17176 STOCKHOLM,SWEDEN

来源：

JOURNAL OF ASSISTED REPRODUCTION AND GENETICS | 1994年 / 11卷 / 09期

关键词：

IN VITRO FERTILIZATION; AGE; OVARIAN STIMULATION; GONADOTROPIN RELEASING HORMONE ANALOGS; CLOMIPHENE CITRATE; HUMAN MENOPAUSAL GONADOTROPIN;

D O I：

10.1007/BF02215711

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Purpose: The aim of this study was to assess if the woman's age influenced IVF treatment outcome when a long GnRHa-hMG or a CC-hMG ovarian stimulation protocol was used, Two hundred women were included in the study, 100 women under the age of 35 and 100 women 35 years of age and older (mean 31.8 years and 36.7 years respectively), In the younger group as well as in the older group 50 women were stimulated according to a GnRHa-hMG protocol and 50 women received a CC-hMG regimen. Results: Significant differences between stimulation protocols were found in the older group for the mean numbers of oocytes recovered (4.7 vs 3.0), preembryos obtained (3.2 vs 2.0) and replaced (2.3 vs 1.7), as well as pregnancy (30% vs 10%) and delivery (24% vs 4%) rates per replacement. Conclusion: It is concluded that women over 35 years of age seem to have a more favorable outcome of NF treatment when using a long GnRHa-hMG protocol compared with CC-hMG, while this difference was not as obvious and lacking statistical significance under the age of 35.

引用

页码：474 / 477

页数：4

共 17 条

[1]

Polson D.W., MacLachlan V., Krapez J.A., Wood C., Healy D.L., A controlled study of gonadotropin-releasing hormone agonist (buserelin acetate) for folliculogenesis in routine in vitro fertilization patients, Fertil Steril, 56, pp. 509-514, (1991)

[2]

Abdalla H.I., Ahuja K.K., Leonard T., Morris N.N., Honour J.W., Jacobs H.S., Comparative trial of luteinizing hormonereleasing hormone analog/human menopausal gonadotropin and clomophene citrate/human menopausal gonadotropin in an assisted conception program, Fertil Steril, 53, pp. 473-478, (1990)

[3]

Kubik C.J., Guzick D.S., Berga S.L., Zeleznik A.J., Randomizrd, prospective trial of leuprolide acetate and conventional superovulation in first cycles of in vitro fertilization and gamete intrafallopian transfer, Fertil Steril, 54, pp. 836-841, (1990)

[4]

Sundstrom P., Wraby H., Evaluation of variations in pregnancy rates, implantation rates and early abortion rates within an in-vitro fertilization programme, Hum Reprod, 4, pp. 443-445, (1989)

[5]

Schwartz D., Mayaux M.J., Female fecundity as a function of age: results of artificial insemination in 2193 nulliparous women with azoospermic husbands, N Engl J Med, 306, pp. 404-406, (1982)

[6]

Meldrum D.R., Female reproductive aging—ovarian and uterine factors, Fertil Steril, 59, pp. 1-5, (1993)

[7]

Navot D., Bergh P.A., Willia M., Garissi G.J., Guzman I., Sandler B., Fox J., Schreiner-Engel P., Hoffman G.E., Grunfeld L., An insight into early reproductive processes through the in vivo model of ovum donation, J Clin Endocrinol Metab, 79, pp. 408-414, (1991)

[8]

Edwards R.G., Fishel S.B., Cohen J., Fehilly C.B., Purdy J.M., Slater J.M., Steptoe P.C., Webster J.M., Factors influencing the success of in vitro fertilization for alleviating human infertility, J in Vitro Fert Embryo Transfer, 1, pp. 3-23, (1984)

[9]

Piette C., de Mouzon J., Bachelot A., Spira A., In-vitro fertilization: influence of women's age on pregnancy rates, Hum Reprod, 5, pp. 56-59, (1990)

[10]

Laufer N., Pratt B.M., DeCherney A.H., Naftolin F., Merino M., Markert C.L., The in vivo and in vitro effects of clomiphene citrate on ovulation, fertilization, and development of cultured mouse oocytes, Am J Obstet Gynecol, 147, pp. 636-639, (1983)

← 1 2 →